|
Title
|
|
|
|
Docetaxel (taxotere(tm)) in advanced gastric-cancer - results of a phase-ii clinical-trial
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m(-2) i.v. over 60 min without premedication, once every 3 weeks. Metastatic sites included the liver in 12 patients and retroperitoneal lymph nodes in 16. Eight of the 33 evaluable patients (24%) achieved a partial remission for a median of 7.5 months (3-11 +). An additional 11 patients had stabilisation of disease. The patients received a median of four cycles of docetaxel (range 1-8) for a total of 156 courses. Dose reduction was necessary in 30 cycles; 14 cycles were delayed a mean of 3 days. Haematological toxicity consisted mainly of non-cumulative neutropenia, with a median nadir count of 0.35 x 10(9) I-1 (0.04-1.64) and eight episodes (5%) of leucopenic fever; non-haematological toxicities included alopecia, mild nausea and vomiting and allergic manifestations such as skin rash and pruritus. There were no drug-related deaths. Our data indicate that docetaxel is an active agent in advanced gastric cancer; further clinical investigations seem warranted. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
The British journal of cancer. - London
| |
|
Publication
|
|
|
|
London
:
1994
| |
|
ISSN
|
|
|
|
0007-0920
| |
|
DOI
|
|
|
|
10.1038/BJC.1994.310
| |
|
Volume/pages
|
|
|
|
70
:2
, p. 380-383
| |
|
ISI
|
|
|
|
A1994PA75300035
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|